Floatz logo

Befotertinib

Carboplatin

Peng ZhangPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Carboplatin cohort.

Asset / SponsorPhaseRating
Carboplatin
AstraZeneca
Phase 1CC
Olaparib
AstraZeneca
Phase 1CC

Same molecule, other indications

Befotertinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
EGFR Sensitive MutationDormant
B
Indicative ·
60 / 100
View asset →
EGFR Gene MutationDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →